ライフサイエンスコーパス: human immunodeficiency virus type 1

1 s been found previously to interact with the human immunodeficiency virus, type 1 accessory protein V

2 ssociated with BV, such as preterm birth and human immunodeficiency virus type 1 acquisition, are ass

3 41 subunit of the envelope glycoprotein from human immunodeficiency virus type 1, an essential subuni

4 Different viruses, such as human immunodeficiency virus type 1 and hepatitis C viru

5 Serum analysis was negative for human immunodeficiency virus type 1 and type 2 RNA, and

6 Serum analysis was also negative for human immunodeficiency virus type 1 and type 2 RNA, Vene

7 The availability of reliable human immunodeficiency virus types 1 and 2 (HIV-1/2) rap

8 ribe the mechanical responses of vancomycin, human immunodeficiency virus type 1 antigens and coagula

9 Among patients with tuberculosis and human immunodeficiency virus type 1, CD4-stratified init

10 CD4(+) T cells was observed in subjects with human immunodeficiency virus type 1 coinfection without

11 opoietic stem/progenitor cells (HSPCs) using human immunodeficiency virus, type 1-derived lentiviral

12 Human immunodeficiency virus type 1 drug resistance amon

13 Human immunodeficiency virus type 1 enhancer-binding pro

14 lex virus type 2 (HSV-2; herpes) exacerbates human immunodeficiency virus type 1 (HIV) by unclear mec

15 ) alfa plus ribavirin decreases the proviral human immunodeficiency virus type 1 (HIV) DNA level.

16 Transmitted human immunodeficiency virus type 1 (HIV) drug resistanc

17 Intermittent shedding of human immunodeficiency virus type 1 (HIV) in semen occur

18 DSC) expansion and T-cell dysfunction during human immunodeficiency virus type 1 (HIV) infection are

19 Untreated human immunodeficiency virus type 1 (HIV) infection is a

20 Progressive T cell depletion during chronic human immunodeficiency virus type 1 (HIV) infection is a

21 Immune control of human immunodeficiency virus type 1 (HIV) infection is t

22 Human immunodeficiency virus type 1 (HIV) infection subs

23 esses may contribute to morbidity in treated human immunodeficiency virus type 1 (HIV) infection.

24 ormed a cohort study involving patients with human immunodeficiency virus type 1 (HIV) infection.

25 Seventeen mothers had human immunodeficiency virus type 1 (HIV) infection; no

26 Infection with human immunodeficiency virus type 1 (HIV) is associated

27 nt and understudied topic of cell-associated human immunodeficiency virus Type 1 (HIV) mucosal transm

28 whether distinct populations have differing human immunodeficiency virus type 1 (HIV) neutralizing a

29 cable comorbidities are more prevalent among human immunodeficiency virus type 1 (HIV)-infected indiv

30 Human immunodeficiency virus type 1 (HIV)-infected perso

31 s remains a significant cause of death among human immunodeficiency virus type 1 (HIV)-infected perso

32 se mortality among individuals infected with human immunodeficiency virus type 1 (HIV).

33 The human immunodeficiency virus type 1 (HIV-1) accessory pr

34 diated cytotoxicity (ADCC), in prevention of human immunodeficiency virus type 1 (HIV-1) acquisition

35 been shown to be preferentially targeted by human immunodeficiency virus type 1 (HIV-1) and are impl

36 ned elusive for important pathogens, such as human immunodeficiency virus type 1 (HIV-1) and herpesvi

37 ion is an efficient mechanism to disseminate human immunodeficiency virus type 1 (HIV-1) and human T

38 reporter genes delivered by vectors based on human immunodeficiency virus type 1 (HIV-1) and Mason-Pf

39 Binding of human immunodeficiency virus type 1 (HIV-1) and simian i

40 lpha (AgmTRIM5alpha) potently restricts both human immunodeficiency virus type 1 (HIV-1) and simian i

41 ts the infectivity of retroviruses including human immunodeficiency virus type 1 (HIV-1) and the mobi

42 most therapeutic and vaccine candidates for human immunodeficiency virus type 1 (HIV-1) are evaluate

43 Assembly and maturation of the human immunodeficiency virus type 1 (HIV-1) are governed

44 Splicing patterns in human immunodeficiency virus type 1 (HIV-1) are maintain

45 s of this regimen on cellular reservoirs for human immunodeficiency virus type 1 (HIV-1) are unknown.

46 2.0), a real-time polymerase chain reaction human immunodeficiency virus type 1 (HIV-1) assay with h

47 Human immunodeficiency virus type 1 (HIV-1) assembles as

48 ng proteins incorporated into virions during human immunodeficiency virus type 1 (HIV-1) assembly pro

49 Here we show that human immunodeficiency virus type 1 (HIV-1) associates w

50 generally suppresses the replication of the human immunodeficiency virus type 1 (HIV-1) but does not

51 its the release of virions of the retrovirus human immunodeficiency virus type 1 (HIV-1) by tethering

52 restriction activity, each was fused to the human immunodeficiency virus type 1 (HIV-1) CA binding p

53 Although the human immunodeficiency virus type 1 (HIV-1) CA carboxy-t

54 Human immunodeficiency virus type 1 (HIV-1) can efficien

55 Human immunodeficiency virus type 1 (HIV-1) can replicat

56 The human immunodeficiency virus type 1 (HIV-1) capsid prote

57 of measles and associations with outcome and human immunodeficiency virus type 1 (HIV-1) coinfection,

58 BEC3F (A3F) was highly localized into mature human immunodeficiency virus type 1 (HIV-1) cores and id

59 Emerging data relating to human immunodeficiency virus type 1 (HIV-1) cure suggest

60 of preventing perinatal transmission (PT) of human immunodeficiency virus type 1 (HIV-1) depends on b

61 ia A who were exposed to but uninfected with human immunodeficiency virus type 1 (HIV-1) did not reve

62 Human immunodeficiency virus type 1 (HIV-1) disease is a

63 HLA strongly influences human immunodeficiency virus type 1 (HIV-1) disease prog

64 Inflammation in early human immunodeficiency virus type 1 (HIV-1) disease prog

65 Transcriptionally silent human immunodeficiency virus type 1 (HIV-1) DNA persists

66 a number of years that integration sites of human immunodeficiency virus type 1 (HIV-1) DNA show a p

67 Herein, human immunodeficiency virus type 1 (HIV-1) DNA was chos

68 Human immunodeficiency virus type 1 (HIV-1) drug resista

69 Monitoring human immunodeficiency virus type 1 (HIV-1) drug resista

70 Human immunodeficiency virus type 1 (HIV-1) dual infecti

71 inical trial to evaluate the safety and anti-human immunodeficiency virus type 1 (HIV-1) efficacy of

72 Human immunodeficiency virus type 1 (HIV-1) entry into c

73 ing conserved CD4-induced (CD4i) epitopes on human immunodeficiency virus type 1 (HIV-1) Env and able

74 reactivity (ER) describes the propensity of human immunodeficiency virus type 1 (HIV-1) Env to chang

75 The human immunodeficiency virus type 1 (HIV-1) envelope (En

76 the gp120 subunits of a soluble recombinant human immunodeficiency virus type 1 (HIV-1) envelope (En

77 The extraordinary diversity of the human immunodeficiency virus type 1 (HIV-1) envelope (En

78 y simian immunodeficiency virus (SIV) versus human immunodeficiency virus type 1 (HIV-1) envelope ant

79 Although antibodies to the human immunodeficiency virus type 1 (HIV-1) envelope gly

80 Recombinant trimeric mimics of the human immunodeficiency virus type 1 (HIV-1) envelope gly

81 The human immunodeficiency virus type 1 (HIV-1) envelope gly

82 Helper T-cell epitope dominance in human immunodeficiency virus type 1 (HIV-1) envelope gly

83 s between the gp120 and gp41 subunits of the human immunodeficiency virus type 1 (HIV-1) envelope gly

84 Antibodies bound to human immunodeficiency virus type 1 (HIV-1) envelope pro

85 Identifying characteristics of the human immunodeficiency virus type 1 (HIV-1) envelope tha

86 used that target nonoverlapping sites on the human immunodeficiency virus type 1 (HIV-1) envelope.

87 The "shock and kill" model of human immunodeficiency virus type 1 (HIV-1) eradication

88 eservoir represents a critical challenge for human immunodeficiency virus type 1 (HIV-1) eradication

89 s maintained in a quiescent state.IMPORTANCE Human immunodeficiency virus type 1 (HIV-1) establishes

90 Human immunodeficiency virus type 1 (HIV-1) establishes

91 Transmission lies at the interface of human immunodeficiency virus type 1 (HIV-1) evolution wi

92 es maintain the ability to interact with the human immunodeficiency virus type 1 (HIV-1) Gag precurso

93 an T-cell leukemia virus type 1 (HTLV-1) and human immunodeficiency virus type 1 (HIV-1) Gag proteins

94 After human immunodeficiency virus type 1 (HIV-1) gains access

95 Robust activation of human immunodeficiency virus type 1 (HIV-1) gene express

96 ression of a functional miRNA encoded in the human immunodeficiency virus type 1 (HIV-1) genome.

97 velope glycoprotein (Env) trimers of various human immunodeficiency virus type 1 (HIV-1) genotypes ar

98 (Ab) responses against V1V2 epitopes of the human immunodeficiency virus type 1 (HIV-1) gp120 envelo

99 placing the single VSV glycoprotein (G) with human immunodeficiency virus type 1 (HIV-1) gp160 to cre

100 virtide) and other peptides derived from the human immunodeficiency virus type 1 (HIV-1) gp41 C-termi

101 The hydrophobic groove of the human immunodeficiency virus type 1 (HIV-1) gp41 NHR tri

102 The life cycle of the human immunodeficiency virus type 1 (HIV-1) has an absol

103 The origins of human immunodeficiency virus type 1 (HIV-1) have been wi

104 Human immunodeficiency virus type 1 (HIV-1) hijacks host

105 Human immunodeficiency virus type 1 (HIV-1) impairs majo

106 motif-containing protein 5 (TRIM5) restricts human immunodeficiency virus type 1 (HIV-1) in a species

107 al components of vaccine-induced immunity to human immunodeficiency virus type 1 (HIV-1) in humans an

108 % of genetically linked infections caused by human immunodeficiency virus type 1 (HIV-1) in serodisco

109 iously shown to decrease the accumulation of human immunodeficiency virus type 1 (HIV-1) in the super

110 About 10% of new diagnoses of subtype B human immunodeficiency virus type 1 (HIV-1) in the Unite

111 In the absence of therapy, CXCR4 (X4)-tropic human immunodeficiency virus type 1 (HIV-1) increases ov

112 s chronic infection with RNA viruses such as human immunodeficiency virus type 1 (HIV-1) induces prof

113 ed antiretroviral therapy (cART) in semen of human immunodeficiency virus type 1 (HIV-1) infected men

114 usceptible tuberculosis in a setting of high human immunodeficiency virus type 1 (HIV-1) infection an

115 n are recognized as important in controlling human immunodeficiency virus type 1 (HIV-1) infection an

116 rs in early childhood and is associated with human immunodeficiency virus type 1 (HIV-1) infection an

117 al therapy (cART) administered shortly after human immunodeficiency virus type 1 (HIV-1) infection ca

118 Guidelines for treatment of human immunodeficiency virus type 1 (HIV-1) infection co

119 iescent proviral genomes that persist during human immunodeficiency virus type 1 (HIV-1) infection de

120 Research toward a cure for human immunodeficiency virus type 1 (HIV-1) infection ha

121 hylaxis has been shown to reduce the risk of human immunodeficiency virus type 1 (HIV-1) infection in

122 Human immunodeficiency virus type 1 (HIV-1) infection in

123 A hallmark of human immunodeficiency virus type 1 (HIV-1) infection in

124 Human immunodeficiency virus type 1 (HIV-1) infection is

125 Chronic human immunodeficiency virus type 1 (HIV-1) infection is

126 Human immunodeficiency virus type 1 (HIV-1) infection is

127 Human immunodeficiency virus type 1 (HIV-1) infection is

128 Human immunodeficiency virus type 1 (HIV-1) infection is

129 The initial phases of acute human immunodeficiency virus type 1 (HIV-1) infection ma

130 Human immunodeficiency virus type 1 (HIV-1) infection of

131 Human immunodeficiency virus type 1 (HIV-1) infection of

132 A vaccine that protects against human immunodeficiency virus type 1 (HIV-1) infection sh

133 ciency virus (SIV) infection and humans with human immunodeficiency virus type 1 (HIV-1) infection th

134 identified as a late postentry suppressor of human immunodeficiency virus type 1 (HIV-1) infection, i

135 potent anti-retroviral drugs in controlling human immunodeficiency virus type 1 (HIV-1) infection, l

136 rial of preexposure chemoprophylaxis against human immunodeficiency virus type 1 (HIV-1) infection, t

137 al contraceptives regulate susceptibility to human immunodeficiency virus type 1 (HIV-1) infection, t

138 e HCV infection in participants with chronic human immunodeficiency virus type 1 (HIV-1) infection.

139 ophylaxis (PrEP) candidate for prevention of human immunodeficiency virus type 1 (HIV-1) infection.

140 cell-based gene modification therapy against human immunodeficiency virus type 1 (HIV-1) infection.

141 source of type I IFN (IFN-I) in response to human immunodeficiency virus type 1 (HIV-1) infection.

142 ired T-cell function was investigated during human immunodeficiency virus type 1 (HIV-1) infection.

143 interventions to prevent the acquisition of human immunodeficiency virus type 1 (HIV-1) infection.

144 ete roles and functions of DRFs during early human immunodeficiency virus type 1 (HIV-1) infection.

145 of CD4+ T lymphocytes, a major reservoir for human immunodeficiency virus type 1 (HIV-1) infection.

146 ed as prophylaxis can prevent acquisition of human immunodeficiency virus type 1 (HIV-1) infection.

147 High numbers of human immunodeficiency virus type 1 (HIV-1) infections a

148 Rhesus macaques are used to model human immunodeficiency virus type 1 (HIV-1) infections,

149 timulated genes (ISGs) and potently suppress Human immunodeficiency virus type 1 (HIV-1) infectivity

150 OBEC3G (A3G) is a human enzyme that inhibits human immunodeficiency virus type 1 (HIV-1) infectivity,

151 The human immunodeficiency virus type 1 (HIV-1) initiates re

152 Dolutegravir (DTG), a once-daily, human immunodeficiency virus type 1 (HIV-1) integrase in

153 ointestinal mucosa is the primary site where human immunodeficiency virus type 1 (HIV-1) invades, amp

154 The outcome after infection with the human immunodeficiency virus type 1 (HIV-1) is a complex

155 nhibiting infection with diverse variants of human immunodeficiency virus type 1 (HIV-1) is a key, as

156 The envelope spike of human immunodeficiency virus type 1 (HIV-1) is a target

157 Human immunodeficiency virus type 1 (HIV-1) is divided i

158 Human immunodeficiency virus type 1 (HIV-1) is pandemic,

159 A hallmark of retroviruses such as human immunodeficiency virus type 1 (HIV-1) is reverse t

160 Reverse transcriptase (RT) of human immunodeficiency virus type 1 (HIV-1) is synthesiz

161 Human immunodeficiency virus type 1 (HIV-1) is the resul

162 Human immunodeficiency virus type 1 (HIV-1) isolates fro

163 GSK3532795 is a second-generation human immunodeficiency virus type 1 (HIV-1) maturation i

164 During human immunodeficiency virus type 1 (HIV-1) maturation,

165 The envelope glycoproteins (Envs) from human immunodeficiency virus type 1 (HIV-1) mediate vira

166 The trimeric envelope glycoproteins of human immunodeficiency virus type 1 (HIV-1) mediate viru

167 Following entry into the target cell, human immunodeficiency virus type 1 (HIV-1) must reverse

168 To establish a productive infection, human immunodeficiency virus type 1 (HIV-1) needs to rev

169 Human immunodeficiency virus type 1 (HIV-1) Nef enhances

170 Minority variant human immunodeficiency virus type 1 (HIV-1) nonnucleosid

171 Sexual transmission of human immunodeficiency virus type 1 (HIV-1) occurs acros

172 The human immunodeficiency virus type 1 (HIV-1) pandemic was

173 impact of CD4+ regulatory T cells (Tregs) on human immunodeficiency virus type 1 (HIV-1) pathogenesis

174 Human immunodeficiency virus type 1 (HIV-1) persists in

175 plication to clinically undetectable levels, human immunodeficiency virus type 1 (HIV-1) persists in

176 otyping success rate was evaluated in 12 828 human immunodeficiency virus type 1 (HIV-1) plasma sampl

177 ic visual display, we examine the changes in human immunodeficiency virus type 1 (HIV-1) plasma viral

178 The gp120 portion of the envelope spike on human immunodeficiency virus type 1 (HIV-1) plays a crit

179 The sequence diversity of human immunodeficiency virus type 1 (HIV-1) presents a f

180 Soluble forms of the human immunodeficiency virus type 1 (HIV-1) primary rece

181 Resistance to human immunodeficiency virus type 1 (HIV-1) protease inh

182 Local Alignment Program (LAP) using 115,118 human immunodeficiency virus type 1 (HIV-1) protease, re

183 ic guide RNAs (gRNAs), can excise integrated human immunodeficiency virus type 1 (HIV-1) provirus fro

184 Little is known about the fraction of human immunodeficiency virus type 1 (HIV-1) proviruses t

185 We sequenced the genome of human immunodeficiency virus type 1 (HIV-1) recovered fr

186 Among these viruses, human immunodeficiency virus type 1 (HIV-1) remains a ma

187 (HCV) infection in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains a me

188 Prevention of the transmission of human immunodeficiency virus type 1 (HIV-1) remains a pr

189 is C virus (HCV) in patients coinfected with human immunodeficiency virus type 1 (HIV-1) remains an u

190 (ART) limits proviral reservoirs, a goal for human immunodeficiency virus type 1 (HIV-1) remission st

191 tissues (LTs) are the principal sites where human immunodeficiency virus type 1 (HIV-1) replicates a

192 Human immunodeficiency virus type 1 (HIV-1) replication

193 main-containing protein 1 (SAMHD1) restricts human immunodeficiency virus type 1 (HIV-1) replication

194 Alpha interferon (IFN-alpha) suppresses human immunodeficiency virus type 1 (HIV-1) replication

195 ymphoid tissues (LTs) are principal sites of human immunodeficiency virus type 1 (HIV-1) replication,

196 Tregs) suppress T-cell immune activation and human immunodeficiency virus type 1 (HIV-1) replication,

197 The stability of the human immunodeficiency virus type 1 (HIV-1) reservoir an

198 ciations of CCR5-Delta32 heterozygosity with human immunodeficiency virus type 1 (HIV-1) reservoir si

199 Limited data exist on human immunodeficiency virus type 1 (HIV-1) resistance i

200 Human immunodeficiency virus type 1 (HIV-1) reverse tran

201 t the ribonuclease (RNase) H activity of the human immunodeficiency virus type 1 (HIV-1) reverse tran

202 All had increased human immunodeficiency virus type 1 (HIV-1) RNA and DNA

203 We measured plasma human immunodeficiency virus type 1 (HIV-1) RNA levels b

204 Full-length human immunodeficiency virus type 1 (HIV-1) RNA serves a

205 Full-length unspliced human immunodeficiency virus type 1 (HIV-1) RNAs serve d

206 thout condom use among 911 African HSV-2 and human immunodeficiency virus type 1 (HIV-1) serodiscorda

207 The 231-residue capsid (CA) protein of human immunodeficiency virus type 1 (HIV-1) spontaneousl

208 ve reduced effectiveness in the treatment of human immunodeficiency virus type 1 (HIV-1) subtype C in

209 Human immunodeficiency virus type 1 (HIV-1) subtype CRF0

210 vir plus 2 nucleos(t)ides for maintenance of human immunodeficiency virus type 1 (HIV-1) suppression.

211 this study was to investigate the effect of human immunodeficiency virus type 1 (HIV-1) Tat on the P

212 s an interferon (IFN)-inducible inhibitor of human immunodeficiency virus type 1 (HIV-1) that acts at

213 ith latency reversing agents (LRAs) enhances human immunodeficiency virus type 1 (HIV-1) transcriptio

214 The majority of human immunodeficiency virus type 1 (HIV-1) transmission

215 atory state has been hypothesized to enhance human immunodeficiency virus type 1 (HIV-1) transmission

216 affect efavirenz pharmacokinetics, maternal human immunodeficiency virus type 1 (HIV-1) treatment ou

217 It is therefore unclear whether human immunodeficiency virus type 1 (HIV-1) vaccination

218 functional antibodies remains a challenge in human immunodeficiency virus type 1 (HIV-1) vaccine deve

219 design are being developed as immunogens in human immunodeficiency virus type 1 (HIV-1) vaccine deve

220 An effective human immunodeficiency virus type 1 (HIV-1) vaccine must

221 The search for an efficacious human immunodeficiency virus type 1 (HIV-1) vaccine rema

222 Increasing the breadth of human immunodeficiency virus type 1 (HIV-1) vaccine-elic

223 to be an important component of a protective human immunodeficiency virus type 1 (HIV-1) vaccine.

224 mune responses and inflammation to candidate human immunodeficiency virus type 1 (HIV-1) vaccines rep

225 Human immunodeficiency virus type 1 (HIV-1) vaccines tha

226 A limited number of human immunodeficiency virus type 1 (HIV-1) variants ini

227 Recent studies have evaluated cumulative human immunodeficiency virus type 1 (HIV-1) viral load (

228 A recent study showed that human immunodeficiency virus type 1 (HIV-1) viral protei

229 Though the steps of human immunodeficiency virus type 1 (HIV-1) virion matur

230 important role in regulating the assembly of human immunodeficiency virus type 1 (HIV-1) virus partic

231 sensitive to the prototypic viral antagonist human immunodeficiency virus type 1 (HIV-1) Vpu.

232 ave shown that infection of cells containing human immunodeficiency virus type 1 (HIV-1) with KSHV le

233 of single-stranded DNA (ssDNA) derived from human immunodeficiency virus type 1 (HIV-1), activated t

234 -cell lymphotropic virus type 1 (HTLV-1) and human immunodeficiency virus type 1 (HIV-1), but arises

235 ergistically induce the expression of latent human immunodeficiency virus type 1 (HIV-1), but studies

236 Among infants exposed to human immunodeficiency virus type 1 (HIV-1), detection o

237 Many viruses, including human immunodeficiency virus type 1 (HIV-1), encode a re

238 The surface envelope glycoprotein (SU) of Human immunodeficiency virus type 1 (HIV-1), gp120(SU) p

239 e strong dependence of retroviruses, such as human immunodeficiency virus type 1 (HIV-1), on host cel

240 nd development of three major model systems [human immunodeficiency virus type 1 (HIV-1), Rous sarcom

241 rs based on the env genes of two isolates of human immunodeficiency virus type 1 (HIV-1), specificall

242 ing delayed progression of disease caused by human immunodeficiency virus type 1 (HIV-1), yet a ligan

243 ess to AIDS, in stark contrast to pathogenic human immunodeficiency virus type 1 (HIV-1)-human and SI

244 lated with rotavirus vaccine responses in 68 human immunodeficiency virus type 1 (HIV-1)-infected (an

245 013 that reported virological outcomes among human immunodeficiency virus type 1 (HIV-1)-infected adu

246 a, has long been known to be elevated in the human immunodeficiency virus type 1 (HIV-1)-infected bra

247 ance cytotoxic T lymphocyte (CTL) evasion in human immunodeficiency virus type 1 (HIV-1)-infected CD4

248 The decay of human immunodeficiency virus type 1 (HIV-1)-infected cel

249 Unlike human immunodeficiency virus type 1 (HIV-1)-infected hum

250 cy virus (SHIV)-infected rhesus macaques and human immunodeficiency virus type 1 (HIV-1)-infected hum

251 alleles (e.g., HLA-B*27) are enriched among human immunodeficiency virus type 1 (HIV-1)-infected ind

252 Human immunodeficiency virus type 1 (HIV-1)-infected ind

253 ssion in the central nervous system (CNS) of human immunodeficiency virus type 1 (HIV-1)-infected ind

254 combination antiretroviral therapy (cART) to human immunodeficiency virus type 1 (HIV-1)-infected inf

255 All human immunodeficiency virus type 1 (HIV-1)-infected ino

256 In human immunodeficiency virus type 1 (HIV-1)-infected peo

257 The aging of the human immunodeficiency virus type 1 (HIV-1)-infected pop

258 ion of combination antiretroviral therapy to human immunodeficiency virus type 1 (HIV-1)-infected pre

259 -blind, placebo-controlled clinical trial on human immunodeficiency virus type 1 (HIV-1)-infected sub

260 In this prospective study, human immunodeficiency virus type 1 (HIV-1)-infected sub

261 are reported in uninfected children born to human immunodeficiency virus type 1 (HIV-1)-infected wom

262 at women on PrEP had IgA with higher average human immunodeficiency virus type 1 (HIV-1)-neutralizing

263 ed infectious virions, non-bNAbs and mucosal human immunodeficiency virus type 1 (HIV-1)-positive IgG

264 onal regulatory T cells (Tregs) can suppress human immunodeficiency virus type 1 (HIV-1)-specific imm

265 tion with an anti-PD-L1 antibody may improve human immunodeficiency virus type 1 (HIV-1)-specific imm

266 e control of intracellular pathogens such as human immunodeficiency virus type 1 (HIV-1).

267 this combination in patients coinfected with human immunodeficiency virus type 1 (HIV-1).

268 he reverse transcriptase (RT) complex of the human immunodeficiency virus type 1 (HIV-1).

269 iciency virus (SIVcpz) into pandemic group M human immunodeficiency virus type 1 (HIV-1).

270 TIs) in treatment-naive adults infected with human immunodeficiency virus type 1 (HIV-1).

271 urfaces of cells infected with vpu-deficient human immunodeficiency virus type 1 (HIV-1).

272 ween herpes simplex virus type 2 (HSV-2) and human immunodeficiency virus type 1 (HIV-1).

273 IVgor, which represent the ape precursors of human immunodeficiency virus type 1 (HIV-1).

274 The human immunodeficiency virus type 1 (HIV-1)/simian immun

275 ck-and-kill" therapeutic approach to reverse human immunodeficiency virus type-1 (HIV) latency from C

276 Human Immunodeficiency Virus type-1 (HIV)-associated neu

277 sease (GUD) in a cohort of women living with human immunodeficiency virus type-1 (HIV-1) in Burkina F

278 Human immunodeficiency virus type-1 (HIV-1)-associated n

279 plays a crucial role in the pathogenesis of human immunodeficiency virus type-1 (HIV-1).

280 a wide range of enveloped viruses, including human immunodeficiency virus, type 1 (HIV-1) by directly

281 -1beta is associated with the progression of human immunodeficiency virus, type 1 (HIV-1) disease or

282 brane-proximal external region (MPER) of the human immunodeficiency virus, type 1 (HIV-1) envelope gl

283 e supposed to form a natural barrier against human immunodeficiency virus, type 1 (HIV-1) infection.

284 y contribute to racial disparities in plasma human immunodeficiency virus type 1 : HIV-1) RNA levels

285 e replication of primate lentiviruses (e.g., human immunodeficiency virus type 1 [HIV-1] and simian i

286 or tenofovir/emtricitabine (TDF/FTC) in 1857 human immunodeficiency virus type 1-infected, treatment-

287 for MICA in progression and elite control of human immunodeficiency virus type 1 infection.

288 be fruitful for this scaffold, since strong human immunodeficiency virus type 1 integrase (HIV-1 IN)

289 virus, reovirus, vesicular stomatitis virus, human immunodeficiency virus type 1, or herpes simplex v

290 96-1997, 1998-1999, 2000-2001], and AIDS and human immunodeficiency virus type 1 RNA at baseline) mor

291 ART-naive subjects with human immunodeficiency virus type 1 RNA load (viral load

292 The role of the adenosine (ADO) pathway in human immunodeficiency virus type 1/simian immunodeficie

293 ized Rous sarcoma virus (RSV) intasomes with human immunodeficiency virus type 1 strand transfer inhi

294 transduction domain of the tat protein from human immunodeficiency virus type 1 (tat-cyclotraxin-B).

295 Importance: Human immunodeficiency virus type 1 transmission is esta

296 HIV-1 (human immunodeficiency virus type 1) uses its trimeric g

297 the clinical development pathway of an rVSV/human immunodeficiency virus type 1 vaccine.

298 Human immunodeficiency virus type 1 Vpr is an accessory

299 at this position and either co-expression of human immunodeficiency virus type 1 vpu or siRNA-mediate

300 Unlike human immunodeficiency virus type 1 Vpu protein, which a